(RTTNews) - Syndax Pharmaceuticals Inc. (SNDX) announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualised rate of decline in forced vital capacity (FVC).
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.